CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Oncomatryx Biopharma develops precision drugs targeting the tumor microenvironment to treat aggressive metastatic solid tumors. Their lead candidate, OMTX705, is in Phase I clinical trials for various cancers, aiming to neutralize immunosuppressive effects and improve treatment outcomes.
Oncomatryx Biopharma SL (ONCOMATRYX) is a cutting-edge biotechnology company established in 2010 in Bilbao, Spain, with the mission to pioneer and develop novel precision drugs targeting the tumour microenvironment for indications of high unmet need.
We strive to change the paradigm in the treatment of some of the most aggressive metastatic solid tumors, by neutralizing the immunosuppressive influence of the tumour microenvironment on cancer cells.
To achieve this goal, we have developed a compr…
ONCOMATRYX BIOPHARMA SA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
